'Swiss drugmaker Roche turned down a potential $14bn-a-year weight-loss pill now being developed by rival Eli Lilly that could have given it a leading position in the booming weight-loss market, according to company filings and people close to discussions.'

https://www.ft.com/content/78057a2c-60b8-410f-8731-b7c787991a57